Muse bio today announced the publication of a paper in Nature Biotechnology describing, for the first time, its foundational technology platform that enables rational engineering of the whole genome with single-nucleotide precision.
The technology, “CRISPR-enabled trackable genome engineering” (CREATE), has been exclusively licensed to Muse bio and is being commercialized as part of its ForgeCraft™ technology. ForgeCraft is a powerful combination of forward design software, a proprietary set of reagents and algorithms, and an automated easy-to-use instrument. Muse bio is already working with key alpha partners to demonstrate the power of the technology, in the research, industrial, agricultural and biopharma markets.